Bionetide - Biomed Industries
Alternative Names: NA-921Latest Information Update: 31 Mar 2025
At a glance
- Originator Biomed Industries
- Class Neuroprotectants; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide 1 modulators; Insulin-like growth factor I modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Obesity; Rett syndrome
Most Recent Events
- 15 Feb 2025 Phase-III clinical trials in Obesity (In children, In adolescents, In adults) in Australia, USA (PO) (NCT06840496)
- 15 Feb 2025 Phase-III clinical trials in Rett syndrome (In adolescents, In children, In adults) in Australia, USA (PO) (NCT06840496)
- 28 Jan 2025 Biomed Industries completes a phase II/III trial in Rett syndrome (In Children, In adolescent, In adults) in USA, Australia (PO, Liquid) (NCT06849973)